RhumbLine Advisers’s Dova Pharmaceuticals DOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-12,827
Closed -$359K – 2965
2019
Q3
$359K Sell
12,827
-100
-0.8% -$1.62K ﹤0.01% 2481
2019
Q2
$182K Sell
12,927
-2,227
-15% -$21.2K ﹤0.01% 2810
2019
Q1
$135K Sell
15,154
-189
-1% -$1.53K ﹤0.01% 2824
2018
Q4
$116K Buy
15,343
+4,843
+46% +$78K ﹤0.01% 2864
2018
Q3
$220K Sell
10,500
-750
-7% -$17.9K ﹤0.01% 2682
2018
Q2
$337K Buy
+11,250
New +$306K ﹤0.01% 2476

RhumbLine Advisers's DOVA Position: Q4 2019 in Review

RhumbLine Advisers sold out of Dova Pharmaceuticals (DOVA) in Q4 2019, closing a stake of 12,827 shares — an estimated $359K sold.

RhumbLine Advisers first reported a position in DOVA in Q2 2018 and held it in 6 quarters. The position peaked at $359K in Q3 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • RhumbLine Advisers reported no remaining Dova Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • RhumbLine Advisers sold 12,827 Dova Pharmaceuticals shares in Q4 2019, an estimated $359K.
  • RhumbLine Advisers first reported a position in Dova Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • RhumbLine Advisers's Dova Pharmaceuticals position peaked at $359K in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals as of Q4 2019.

Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.